|
| Category | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
|
Orphan Drug
|
NIDDK
|
4R33DK070341-03
|
|
Novel Therapies for Resistant FSGS
|
TRACHTMAN, HOWARD
|
FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
|
NY
|
$751,294
|
|
Orphan Drug
|
NCI
|
5R01CA085870-07
|
|
Interaction of uPAR & Integrins in Oral Cancer
|
STACK, MARY
|
UNIVERSITY OF MISSOURI-COLUMBIA
|
MO
|
$224,062
|
|
Orphan Drug
|
NCI
|
5R13CA100041-03
|
|
2003 Molecular Cell Biology Gordon Conference
|
O'SHEA, ERIN
|
GORDON RESEARCH CONFERENCES
|
RI
|
$5,000
|
|
Orphan Drug
|
NINDS
|
5U01NS050094-03
|
|
Characterizing Beta Lactams as Neuroprotectants for Amyotrophic Lateral Sclerosis
|
ROTHSTEIN, JEFFREY
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$322,944
|
|
Orphan Drug
|
NIGMS
|
5F32GM076869-02
|
|
Chemical Biology of BubR1
|
SANDLER, JOEL
|
ROCKEFELLER UNIVERSITY
|
NY
|
$45,976
|
|
Orphan Drug
|
NCI
|
1R21CA114279-01A2
|
|
MRI Assessment of Anti-angiogenesis in Mouse Gliomas
|
PIKE, MARTIN
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$173,250
|
|
Orphan Drug
|
NCI
|
4R37CA042245-23
|
|
Regulation of replication and latency EBV EBNAs
|
HAYWARD, S
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$367,373
|
|
Orphan Drug
|
NIEHS
|
5R01ES015339-02
|
|
Protein Kinase Signaling and Cell Cycle Control
|
YAFFE, MICHAEL
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$352,978
|
|
Orphan Drug
|
NCI
|
5F31CA123711-02
|
|
Targeting ATF5 for intervention in brain cancer
|
ARIAS, ANGELO
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$30,513
|
|
Orphan Drug
|
NIAID
|
5R01AI033537-15
|
|
Virulence Gene Expression by Bacillus anthracis
|
KOEHLER, THERESA
|
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
|
TX
|
$239,055
|
|
Orphan Drug
|
NIGMS
|
5R01GM053960-11
|
|
DNA Lesions as Endogenous Topoisomerase Poisons
|
OSHEROFF, NEIL
|
VANDERBILT UNIVERSITY
|
TN
|
$281,473
|
|
Orphan Drug
|
NIEHS
|
5F32ES014777-02
|
|
Role of estrogen receptor beta in cancer prevention by dietary indole-3-carbinol
|
BENNINGHOFF, ABBY
|
OREGON STATE UNIVERSITY
|
OR
|
$24,398
|
|
Orphan Drug
|
NCI
|
5R01CA085935-08
|
|
Tubulin Mutations and Paclitaxel Resistance
|
CABRAL, FERNANDO
|
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
|
TX
|
$263,242
|
|
Orphan Drug
|
NCI
|
5R01CA107023-04
|
|
Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma
|
PENICHET, MANUEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$300,313
|
|
Orphan Drug
|
NCI
|
5R01CA115965-02
|
|
FHIT Gene Therapy in Cancer Prevention and Treatment
|
CROCE, CARLO
|
OHIO STATE UNIVERSITY
|
OH
|
$228,000
|
|
Orphan Drug
|
NCI
|
5K99CA126173-02
|
|
Roles of the Checkpoint Kinase Chk1 in Cancer Biology and Therapy
|
ZHANG, YOU-WEI
|
SALK INSTITUTE FOR BIOLOGICAL STUDIES
|
CA
|
$96,874
|
|
Orphan Drug
|
NCI
|
5R01CA121327-02
|
|
Molecular Basis Of Renal Cell Carcinoma Response to SU11428
|
MOTZER, ROBERT
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$346,940
|
|
Orphan Drug
|
NIDCD
|
5R01DC005827-05
|
|
Genetics of Age-Related Hearing Loss
|
JOHNSON, KENNETH
|
JACKSON LABORATORY
|
ME
|
$312,909
|
|
Orphan Drug
|
NIDDK
|
5R01DK070790-03
|
|
Renal Osteodystrophy and Vascular Calcification
|
HRUSKA, KEITH
|
WASHINGTON UNIVERSITY
|
MO
|
$296,512
|
|
Orphan Drug
|
NIAID
|
5K23AI067567-03
|
|
Rebuilding immunity
|
AQUI, NICOLE
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$133,029
|
|
Orphan Drug
|
NCI
|
5R01CA112337-04
|
|
Colon Cancer Inhibition by a Class of PPARgamma Agonists
|
SAFE, STEPHEN
|
TEXAS A&M UNIVERSITY SYSTEM
|
TX
|
$226,255
|
|
Orphan Drug
|
NCI
|
5R01CA124621-02
|
|
Role of Arsenic Trioxide in Primary Effusion Lymphoma
|
CHAUDHARY, PREET
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$278,353
|
|
Orphan Drug
|
NIDDK
|
5R01DK048252-15
|
|
Pathophysiology of Distal Tyrosine Pathway Disorders
|
GROMPE, MARKUS
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$308,500
|
|
Orphan Drug
|
NICHD
|
8R01HD058299-26
|
|
Hepatic Drug Elimination in Pregnancy
|
VORE, MARY
|
UNIVERSITY OF KENTUCKY
|
KY
|
$330,211
|
|
Orphan Drug
|
NCI
|
5R01CA106532-04
|
|
Complex ganglioside function in neuroblastoma
|
LADISCH, STEPHAN
|
CHILDREN'S RESEARCH INSTITUTE
|
DC
|
$247,903
|
|
Orphan Drug
|
NCI
|
5R01CA106662-04
|
|
Dendritic Cell Threapy for Cutaneous T-Cell Lymphoma
|
FALO, LOUIS
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$288,651
|
|
Orphan Drug
|
NHLBI
|
5R01HL084153-02
|
|
Focal Adhesion Kinase Regulation of Lung Vascular Permeability and Edemagenesis
|
MEHTA, DOLLY
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$387,500
|
|
Orphan Drug
|
NCI
|
5F31CA113268-03
|
|
HTS for Small Molecule Inhibitors of the RhoA Pathway
|
EVELYN, CHRIS
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$32,641
|
|
Orphan Drug
|
NCI
|
5U01CA062407-14
|
|
Therapeutics Studies of Primary CNS Malignancies
|
WEN, PATRICK
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$142,136
|
|
Orphan Drug
|
NIEHS
|
5R01ES015294-02
|
|
Defining the roles of macrophages subsets and NK lymphocytes in silicosis
|
HOLIAN, ANDRIJ
|
UNIVERSITY OF MONTANA
|
MT
|
$308,160
|
|
Orphan Drug
|
NHLBI
|
5R01HL052173-11
|
|
Regulation of Factor VIII Secretion
|
KAUFMAN, RANDAL
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$379,783
|
|
Orphan Drug
|
NHLBI
|
5R01HL079023-04
|
|
Enhancing hepatocyte gene transfer for Hemophilia A
|
MCCRAY, PAUL
|
UNIVERSITY OF IOWA
|
IA
|
$274,118
|
|
Orphan Drug
|
NCI
|
5R01CA112519-03
|
|
Novel Targeted Therapeutics for Cental Nervous System Malignancies
|
ALI-OSMAN, FRANCIS
|
DUKE UNIVERSITY
|
NC
|
$327,069
|
|
Orphan Drug
|
NCI
|
5R01CA032685-24
|
|
Clinical Development of Hu14.18-IL2 Targeted Therapy
|
SONDEL, PAUL
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$308,597
|
|
Orphan Drug
|
NCI
|
5F31CA119938-03
|
|
Paclitaxel Carrier from Protein Library
|
GRESHAM, VENITA
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$28,035
|
|
Orphan Drug
|
NCI
|
4R37CA011898-38
|
|
Brain Tumors - Immunological and Biological Studies
|
BIGNER, DARELL
|
DUKE UNIVERSITY
|
NC
|
$670,357
|
|
Orphan Drug
|
NICHD
|
5R01HD044859-04
|
|
Post-translational regulation of CYP17 activity
|
MAGOFFIN, DENIS
|
CEDARS-SINAI MEDICAL CENTER
|
CA
|
$308,066
|
|
Orphan Drug
|
NIDCD
|
5R01DC008651-02
|
|
A preclinical trial of intratympanic antivirals for CMV-related hearing loss
|
CHOO, DANIEL
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
OH
|
$314,284
|
|
Orphan Drug
|
NIAID
|
5U01AI061260-04
|
|
VSV as a vector for cytokine-assisted tularemia vaccines
|
MILLER, MARK
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
TN
|
$582,057
|
|
Orphan Drug
|
NCI
|
5R01CA106439-05
|
|
STATs as a Novel Approach to Cancer Therapy
|
TURKSON, JAMES
|
UNIVERSITY OF CENTRAL FLORIDA
|
FL
|
$235,295
|
|
Orphan Drug
|
NCI
|
5R01CA109136-03
|
|
Novel Mechanisms of Carcinoma Cell Migration
|
O'CONNOR, KATHLEEN
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
TX
|
$260,253
|
|
Orphan Drug
|
NCI
|
5R37CA034992-26
|
|
CHEMISTRY AND BIOLOGY OF PLATINUM ANTICANCER DRUGS
|
LIPPARD, STEPHEN
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$672,247
|
|
Orphan Drug
|
NCI
|
5R01CA112483-02
|
|
Inhibition of Prenylated Protein Processing
|
GIBBS, RICHARD
|
PURDUE UNIVERSITY WEST LAFAYETTE
|
IN
|
$260,775
|
|
Orphan Drug
|
NIGMS
|
5R01GM065284-06
|
|
Hydrotropic polymers for oral delivery of paclitaxel
|
PARK, KINAM
|
PURDUE UNIVERSITY WEST LAFAYETTE
|
IN
|
$276,048
|
|
Orphan Drug
|
NIAID
|
5R01AI054711-04
|
|
New Approaches to Schistosome vaccine antigen discovery
|
KING, CHRISTOPHER
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$385,690
|
|
Orphan Drug
|
NIGMS
|
5R37GM040198-24
|
|
FORMATION,INTERACTION & FUNCTION OF SPINDLE COMPONENTS
|
RIEDER, CONLY
|
WADSWORTH CENTER
|
NY
|
$428,636
|
|
Orphan Drug
|
NCI
|
5R01CA104333-04
|
|
DNA Mismatch Repair Deficiency and Leukemia Relapse
|
GU, LIYA
|
UNIVERSITY OF KENTUCKY
|
KY
|
$253,918
|
|
Orphan Drug
|
NCI
|
5U01CA105663-05
|
|
Participating Member Institution in NABTC
|
DEANGELIS, LISA
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$169,613
|
|
Orphan Drug
|
NINDS
|
5R01NS055337-02
|
|
Treatment of Demyelinating Disease with HSP90 Inhibitors
|
FEINSTEIN, DOUGLAS
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$305,156
|
|
Orphan Drug
|
NCI
|
5U01CA076607-10
|
|
Therapeutic Studies of Anaplastic Gliomas
|
NABORS, LOUIS
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$119,037
|
|
Orphan Drug
|
NCI
|
5R01CA118498-03
|
|
Chemical genetic modifiers of acute myelogenous leukemia
|
PETERSON, RANDALL
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$223,027
|
|
Orphan Drug
|
NIA
|
5R01AG018917-06
|
|
A Multidisciplinary Analysis of Gelsolin Amyloid Disease
|
KELLY, JEFFERY
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$501,754
|
|
Orphan Drug
|
NCI
|
5R01CA114103-04
|
|
Biomarkers and Therapeutic Targets in Pancreatic Cancer
|
WHANG, EDWARD
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$287,037
|
|
Orphan Drug
|
NCI
|
5R01CA042056-25
|
|
Antitumor Antibiotics
|
BOGER, DALE
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$458,616
|
|
Orphan Drug
|
NCI
|
5R21CA125181-02
|
|
alphaBeta-crystallin: A Novel Biomarker in Breast Cancer
|
CRYNS, VINCENT
|
NORTHWESTERN UNIVERSITY
|
IL
|
$151,000
|
|
Orphan Drug
|
NIDDK
|
5R01DK033351-23
|
|
Vitamin D Hormone Signaling in Bone Mineral Homeostasis
|
HAUSSLER, MARK
|
UNIVERSITY OF ARIZONA
|
AZ
|
$284,160
|
|
Orphan Drug
|
NCI
|
5U01CA062406-14
|
|
NABTT-New Approaches to Brain Tumor Therapy (CNSC)
|
BATCHELOR, TRACY
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$57,838
|
|
Orphan Drug
|
NINDS
|
5R01NS057412-02
|
|
Suppression of the Idua-W402X mutation in an MPS I-H mouse
|
BEDWELL, DAVID
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$317,188
|
|
Orphan Drug
|
NCI
|
5R01CA114021-03
|
|
Antitumor Antimitotics That Reverse Tumor Resistance
|
GANGJEE, ALEEM
|
DUQUESNE UNIVERSITY
|
PA
|
$247,872
|
|
Orphan Drug
|
NINDS
|
5R01NS054120-03
|
|
A Novel Orally Administered Macrophage Delivered Gene Therapy for Gaucher Disease
|
GINNS, EDWARD
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$319,521
|
|
Orphan Drug
|
NCI
|
5R01CA125541-02
|
|
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
|
SALGIA, RAVI
|
UNIVERSITY OF CHICAGO
|
IL
|
$262,485
|
|
Orphan Drug
|
NCI
|
5U01CA105695-05
|
|
Consortium Therapeutic Studies of Primary Central Nervous System Malignancies
|
CLOUGHESY, TIMOTHY
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$146,647
|
|
Orphan Drug
|
NIDCR
|
5R01DE016665-04
|
|
Targeting KSHV processivity to prevent oral KS in AIDS
|
RICCIARDI, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$297,267
|
|
Orphan Drug
|
NCI
|
5R21CA115568-02
|
|
Design of targeted cell vehicles to ovarian carcinoma
|
PEREBOEVA, LARISA
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$174,600
|
|
Orphan Drug
|
NIDDK
|
1R01DK075294-01A2
|
|
Structure-Based Design of Small Molecules for Aspartylglucosaminuria
|
GUO, HWAI-CHEN
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
MA
|
$309,181
|
|
Orphan Drug
|
NIGMS
|
1SC2CA138179-01
|
|
Biodegradable Polymeric Nanosphere Drug Delivery System For Cancer Chemotherapy
|
AKALA, EMMANUEL
|
HOWARD UNIVERSITY
|
DC
|
$148,000
|
|
Orphan Drug
|
NINDS
|
5U01NS045806-05
|
|
Combination Drug Therapy in Huntington's Disease
|
FERRANTE, ROBERT
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
MA
|
$594,653
|
|
Orphan Drug
|
NICHD
|
5R01HD048895-05
|
|
Genetic and Molecular Basis of Congenital Contractures
|
BAMSHAD, MICHAEL
|
UNIVERSITY OF WASHINGTON
|
WA
|
$309,702
|
|
Orphan Drug
|
NCI
|
1SC2CA137845-01
|
|
The Role of Pim Kinases as a Novel Molecular Target in Pancreatic Cancer
|
BAINES, ANTONIO
|
NORTH CAROLINA CENTRAL UNIVERSITY
|
NC
|
$92,881
|
|
Orphan Drug
|
NINDS
|
5R21NS051408-02
|
|
HIGH-RISK NEUROBLASTOMA: A DEVASTATING CHILDHOOD CANCER
|
BRARD, LAURENT
|
WOMEN AND INFANTS HOSPITAL-RHODE ISLAND
|
RI
|
$182,831
|
|
Orphan Drug
|
NINDS
|
5R21NS054143-02
|
|
Targeted Toxin for Brain Cancer Gene Therapy
|
CASTRO, MARIA
|
CEDARS-SINAI MEDICAL CENTER
|
CA
|
$208,688
|
|
Orphan Drug
|
NCI
|
5R01CA076183-06
|
|
Targeting diffuse liver metastases with Herpes virus
|
TANABE, KENNETH
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$375,113
|
|
Orphan Drug
|
NLM
|
1R21LM009706-01
|
|
Integrating Genomic Data and Biological Knowledge to Learn Context-Specific Gene
|
KIM, SEUNGCHAN
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
AZ
|
$183,012
|
|
Orphan Drug
|
NCI
|
1R01CA130817-01
|
|
Interplay Between Cancer and Immune Cells on Targeted Therapy
|
LEE, PETER
|
STANFORD UNIVERSITY
|
CA
|
$435,170
|
|
Orphan Drug
|
NCI
|
5R01CA113882-03
|
|
Biomarkers for the Progression of Head and Neck Squamous Cell Carcinoma
|
NOWAK, NORMA
|
ROSWELL PARK CANCER INSTITUTE CORP
|
NY
|
$296,644
|
|
Orphan Drug
|
NIAID
|
5R01AI067359-03
|
|
Characterization of Aspergillus fumigatus specific CD4 T cell responses.
|
PAMER, ERIC
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$434,840
|
|
Orphan Drug
|
NEI
|
5R01EY008061-22
|
|
PHOTOTRANSDUCTION ENZYMES
|
PALCZEWSKI, KRZYSZTOF
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$647,301
|
|
Orphan Drug
|
NINDS
|
5R01NS054578-03
|
|
Inflammatory mechanisms associated with HIV-1 dementia
|
MAGGIRWAR, SANJAY
|
UNIVERSITY OF ROCHESTER
|
NY
|
$337,498
|
|
Orphan Drug
|
NCI
|
5R01CA113519-03
|
|
Targeting TGF-beta Signaling in Lung Cancer
|
DATTA, PRAN
|
VANDERBILT UNIVERSITY
|
TN
|
$238,105
|
|
Orphan Drug
|
NINDS
|
5U01NS049640-04
|
|
Clinical Trial of Ceftriaxone in ALS
|
CUDKOWICZ, MERIT
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$6,125,934
|
|
Orphan Drug
|
NCI
|
5R01CA112385-04
|
|
Pharmacodynamic Assessment of RTK Inhibitors in Cancer
|
HALLAHAN, DENNIS
|
VANDERBILT UNIVERSITY
|
TN
|
$258,707
|
|
Orphan Drug
|
NCI
|
5R01CA086335-07
|
|
Therapeutic modulation of angiogenesis in human gliomas
|
VAN MEIR, ERWIN
|
EMORY UNIVERSITY
|
GA
|
$318,638
|
|
Orphan Drug
|
NCI
|
2P01CA087971-06A1
|
0007
|
Real-Time Optical Diagnostics of Tissue for PDT Dosimetry and Treatment Character
|
YODH, ARJUN
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$204,828
|
|
Orphan Drug
|
NCI
|
5R37CA072614-12
|
|
Translational Investigation of KRas & NF1 in Myeloid Leukemia
|
SHANNON, KEVIN
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$309,845
|
|
Orphan Drug
|
NIDDK
|
5K08DK065929-05
|
|
Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets
|
LOECHNER, KAREN
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$126,183
|
|
Orphan Drug
|
NIAID
|
5R01AI056326-05
|
|
Anti-tick-borne Encephalitis Virus Miniprotein Agents
|
FOX, ROBERT
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
TX
|
$351,137
|
|
Orphan Drug
|
NCI
|
5R01CA107568-22
|
|
Hec1 network as molecular therapeutic targets
|
LEE, WEN-HWA
|
UNIVERSITY OF CALIFORNIA IRVINE
|
CA
|
$343,708
|
|
Orphan Drug
|
NCI
|
5R01CA113860-03
|
|
Role of coactivators in cell growth and tumorigenesis
|
CHEN, HONGWU
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$227,408
|
|
Orphan Drug
|
NIAID
|
5R01AI030010-17
|
|
Ehrilchiacidal Mechanisms In Leukocytes
|
RIKIHISA, YASUKO
|
OHIO STATE UNIVERSITY
|
OH
|
$312,886
|
|
Orphan Drug
|
NIAID
|
5R01AI059663-03
|
|
Monoclonal antibodies to inhibit Aspergillus germination
|
FELDMESSER, MARTA
|
YESHIVA UNIVERSITY
|
NY
|
$395,309
|
|
Orphan Drug
|
NCI
|
1R01CA130940-01
|
|
Targeting the Fn14-Rac1 signaling pathway in invasive gliomas
|
TRAN, NHAN
|
TRANSLATIONAL GENOMICS RESEARCH INST
|
AZ
|
$300,668
|
|
Orphan Drug
|
NCI
|
5R01CA108585-03
|
|
Armed Replicating Ad for Breast Cancer Bone Metastasis
|
DOUGLAS, JOANNE
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$225,695
|
|
Orphan Drug
|
NCI
|
1R01CA131081-01
|
|
Disrupting the AF4-AF9 protein complex in MLL leukemias.
|
HEMENWAY, CHARLES
|
LOYOLA UNIVERSITY CHICAGO
|
IL
|
$129,195
|
|
Orphan Drug
|
NHLBI
|
5R01HL087166-02
|
|
Role of TLR Signaling in Ureaplasma-Mediated Neonatal Lung Injury
|
VISCARDI, ROSE
|
UNIVERSITY OF MARYLAND BALTIMORE
|
MD
|
$359,125
|
|
Orphan Drug
|
NIAID
|
5R21AI073317-02
|
|
Antiviral Therapy for Polyomavirus Infection
|
LUKACHER, ARON
|
EMORY UNIVERSITY
|
GA
|
$225,140
|
|
Orphan Drug
|
NCI
|
5R01CA104035-04
|
|
A Novel Inhibitor of Stat3 for Prostate Cancer Therapy
|
JING, NAIJIE
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$280,899
|
|
Orphan Drug
|
NHLBI
|
5K23HL084054-02
|
|
Improving Allogenic Transplant Outcomes in Myeloid Malignancies
|
SCOTT, BART
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$136,485
|
|
Orphan Drug
|
NCI
|
5R01CA079756-08
|
|
P53-Mediated G1/M Checkpoint Controls Altered by PPM1D
|
MERCER, W
|
THOMAS JEFFERSON UNIVERSITY
|
PA
|
$238,892
|
|
Orphan Drug
|
NCI
|
5R01CA096796-06
|
|
Molecular Mechanisms in Chrondrosarcoma Metastasis
|
SCULLY, SEAN
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
FL
|
$294,483
|
|
Orphan Drug
|
NCI
|
5U24CA055727-14
|
|
Childhood Cancer Survivor Study
|
ROBISON, LESLIE
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
TN
|
$4,640,641
|
|
Orphan Drug
|
NCI
|
1R01CA131199-01
|
|
Small Animal Image-Guided Radiotherapy
|
GRAVES, EDWARD
|
STANFORD UNIVERSITY
|
CA
|
$327,884
|
|
Orphan Drug
|
NCI
|
5R01CA125658-02
|
|
Rac GTPases as Targets in Lymphomagenesis
|
ZHENG, YI
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
OH
|
$285,000
|
|
Orphan Drug
|
NCI
|
5R01CA109069-03
|
|
Targeting Tumor Angiogenesis with G-Quadruplex Binders
|
SUN, DAEKYU
|
UNIVERSITY OF ARIZONA
|
AZ
|
$260,253
|
|
Orphan Drug
|
NHLBI
|
5R01HL078564-03
|
|
Functional analysis of Tgfbm3 locus in vascular development and disease
|
AKHURST, ROSEMARY
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$547,678
|
|
Orphan Drug
|
NIDDK
|
5R01DK074368-03
|
|
Mitochondrial Myopathy and Sideroblastic Anemia
|
FISCHEL-GHODSIAN, NATHAN
|
CEDARS-SINAI MEDICAL CENTER
|
CA
|
$299,544
|
|
Orphan Drug
|
NIAID
|
5R01AI059572-03
|
|
Potent and Safe Inhibitors of B. anthracis Lethal Factor
|
PELLECCHIA, MAURIZIO
|
BURNHAM INSTITUTE FOR MEDICAL RESEARCH
|
CA
|
$626,723
|
|
Orphan Drug
|
NIDDK
|
1R01DK077186-01A1
|
|
Role of the cdx homeobox genes in the regulation of wt1 and nephron development
|
DAVIDSON, ALAN
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$350,500
|
|
Orphan Drug
|
NEI
|
1R01EY018656-01
|
|
Compacted DNA Nanoparticles for Ocular Therapy
|
NAASH, MUNA
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
OK
|
$366,250
|
|
Orphan Drug
|
NCI
|
5R37CA044848-22
|
|
Antitumor-Antibiotics from Marine Microorganisms
|
FENICAL, WILLIAM
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$360,308
|
|
Orphan Drug
|
NCI
|
1R01CA131378-01
|
|
Novel Sulindac Derivatives for Colon Cancer Chemoprevention
|
PIAZZA, GARY
|
SOUTHERN RESEARCH INSTITUTE
|
AL
|
$643,885
|
|
Orphan Drug
|
NHLBI
|
5K24HL086796-02
|
|
Proteomic-based Approach to Ventilator Associated Pneumonia
|
SCHNAPP, LYNN
|
UNIVERSITY OF WASHINGTON
|
WA
|
$155,332
|
|
Orphan Drug
|
NCI
|
5R01CA115197-04
|
|
EGFR Targeted Nanoparticles to Overcome Paclitaxel Resistant Breast Cancer
|
MUMPER, RUSSELL
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$235,901
|
|
Orphan Drug
|
NICHD
|
5R01HD020521-22
|
|
Molecular Cloning of the Fragile X Site
|
WARREN, STEPHEN
|
EMORY UNIVERSITY
|
GA
|
$565,995
|
|
Orphan Drug
|
NIGMS
|
5R01GM079359-02
|
|
Development of molecular probes for biomedical applications
|
TAN, WEIHONG
|
UNIVERSITY OF FLORIDA
|
FL
|
$284,263
|
|
Orphan Drug
|
NCI
|
5K24CA106349-04
|
|
Development of Mechanism-Based Anticancer Therapy
|
ECKHARDT, S
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$188,965
|
|
Orphan Drug
|
NCI
|
5R01CA100933-05
|
|
ANALYSIS OF Id GENE TARGETS IN TUMOR ENDOTHELIAL CELLS
|
MITTAL, VIVEK
|
COLD SPRING HARBOR LABORATORY
|
NY
|
$296,523
|
|
Orphan Drug
|
NCI
|
5R01CA100101-03
|
|
SYNTHESIS OF ANTICANCER AGENTS
|
NICOLAOU, K.
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$494,739
|
|
Orphan Drug
|
NIAMS
|
1R21AR055725-01
|
|
Use of matrix metalloproteinase to improve myogenic cell transplantation in MDX m
|
LI, YONG
|
CHILDREN'S HOSP PITTSBURGH/UPMC HLTH SYS
|
PA
|
$179,850
|
|
Orphan Drug
|
NINDS
|
1R01NS061014-01
|
|
Histamine Receptor Signaling in CNS Autoimmune Disease
|
TEUSCHER, CORY
|
UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
|
VT
|
$625,711
|
|
Orphan Drug
|
NINDS
|
5R01NS027941-19
|
|
A MULTICENTER STUDY OF IDIOPATHIC GENERALIZED EPILEPSY
|
GREENBERG, DAVID
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$877,549
|
|
Orphan Drug
|
NCI
|
5R01CA127622-02
|
|
Salinosporamide Biosynthesis and Engineering
|
MOORE, BRADLEY
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$280,761
|
|
Orphan Drug
|
NCI
|
1K99CA131503-01
|
|
Transcriptional regulation of leukemic stem cells in acute myeloid leukemia
|
STEIDL, ULRICH
|
YESHIVA UNIVERSITY
|
NY
|
$140,535
|
|
Orphan Drug
|
NIDDK
|
1R21DK080321-01
|
|
HTS to discover drugs effecting protein folding in the endoplasmic reticulum
|
PAPA, FEROZ
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$231,500
|
|
Orphan Drug
|
NCI
|
5R01CA106512-05
|
|
Allogeneic T Cell Responses Against Renal Cell Carcinoma
|
WARREN, EDUS
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$302,644
|
|
Orphan Drug
|
NCI
|
5R21CA114978-02
|
|
A Therapeutic Vaccine for HPV 16-Positive Head and Neck Cancer
|
GILLISON, MAURA
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$265,009
|
|
Orphan Drug
|
NHLBI
|
5R01HL083515-02
|
|
Ras signaling in leukemogenesis
|
REN, RUIBAO
|
BRANDEIS UNIVERSITY
|
MA
|
$340,971
|
|
Orphan Drug
|
NINDS
|
5R01NS037704-10
|
|
Molecular Markers as Predictors of Outcome in Gliomas
|
POLLACK, IAN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$324,435
|
|
Orphan Drug
|
NHLBI
|
5R01HL083155-02
|
|
Identification of genetic modifiers of heart disease
|
MARCHUK, DOUGLAS
|
DUKE UNIVERSITY
|
NC
|
$390,000
|
|
Orphan Drug
|
NINDS
|
5R01NS032677-16
|
|
Genetically Engineered Viruses for Brain Tumor Therapy
|
MARTUZA, ROBERT
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$376,250
|
|
Orphan Drug
|
NCI
|
5R01CA114535-03
|
|
RecqL4, chromosome instability and cancer predisposition
|
LUO, GUANGBIN
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$266,285
|
|
Orphan Drug
|
NCI
|
5R01CA109254-04
|
|
Drug-Induced Destabilization of Bcl-2 mRNA
|
FERNANDES, DANIEL
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
SC
|
$264,795
|
|
Orphan Drug
|
NICHD
|
1R21HD057402-01
|
|
Optimization of drug-like compounds for treatment of spinal muscular atrophy
|
ANDROPHY, ELLIOT
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$225,000
|
|
Orphan Drug
|
NCI
|
1R21CA131999-01
|
|
Targeting cancer stem cells for brain tumor therapy
|
YU, JOHN
|
CEDARS-SINAI MEDICAL CENTER
|
CA
|
$182,813
|
|
Orphan Drug
|
NIA
|
5R01AG029601-02
|
|
Nanoscale Electrostatic Assemblies for Multi-Agent Drug Delivery from
|
HAMMOND, PAULA
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$313,256
|
|
Orphan Drug
|
NCI
|
5R01CA113930-03
|
|
Metabolic Syndrome in Childhood Cancer Survivors
|
STEINBERGER, JULIA
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$504,537
|
|
Orphan Drug
|
NCI
|
5R01CA114199-04
|
|
Src Kinases in Ph+ Lymphoblastic Leukemia
|
LI, SHAOGUANG
|
JACKSON LABORATORY
|
ME
|
$284,832
|
|
Orphan Drug
|
NCI
|
5R01CA109518-04
|
|
Cellular Targets for Gallium Compounds in Lymphoma
|
CHITAMBAR, CHRISTOPHER
|
MEDICAL COLLEGE OF WISCONSIN
|
WI
|
$255,337
|
|
Orphan Drug
|
NICHD
|
5K23HD052774-02
|
|
Anosognosia for Hemiplegia: Neural Basis, Physchological Correlates, and Recovery
|
KORTTE, KATHLEEN
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$111,509
|
|
Orphan Drug
|
NCI
|
5R01CA116720-03
|
|
Mechanistic Analysis of Papillimavirus E2 Functions
|
HOWLEY, PETER
|
HARVARD UNIVERSITY (MEDICAL SCHOOL)
|
MA
|
$262,923
|
|
Orphan Drug
|
NCI
|
1R21CA132121-01
|
|
Novel Delivery Technology for Potential Drugs for Cervical Cancer
|
TAUTZ, LUTZ
|
BURNHAM INSTITUTE FOR MEDICAL RESEARCH
|
CA
|
$257,850
|
|
Orphan Drug
|
NCI
|
1R01CA131983-01
|
|
High Throughput Microscopy Assays to Identify Inhibitors of Metastasis
|
COURTNEIDGE, SARA
|
BURNHAM INSTITUTE FOR MEDICAL RESEARCH
|
CA
|
$396,325
|
|
Orphan Drug
|
NCI
|
1R21CA131832-01
|
|
Microfluidic Synthesis of Nanoparticles for Oligonucleotide Delivery
|
LEE, ROBERT
|
OHIO STATE UNIVERSITY
|
OH
|
$159,422
|
|
Orphan Drug
|
NIDDK
|
2R01DK059380-07A2
|
|
STAT5 Structure-Function in Hematopoiesis
|
BUNTING, KEVIN
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$300,263
|
|
Orphan Drug
|
NCI
|
5R01CA109733-04
|
|
Molecular Target(s) for Interruption of HBV Infection
|
LI, JISU
|
RHODE ISLAND HOSPITAL (PROVIDENCE, RI)
|
RI
|
$214,052
|
|
Orphan Drug
|
NCI
|
5R01CA114589-04
|
|
Microenvironmental mechanisms of leukemia cell survival
|
LARSON, RICHARD
|
UNIVERSITY OF NEW MEXICO
|
NM
|
$224,720
|
|
Orphan Drug
|
NCI
|
5U10CA013612-35
|
|
SOUTHWEST ONCOLOGY GROUP
|
MILLER, THOMAS
|
UNIVERSITY OF ARIZONA
|
AZ
|
$266,506
|
|
Orphan Drug
|
NCI
|
1R01CA132091-01
|
|
Targeted Nanoparticle DNA Therapy for Ovarian Cancer
|
SAWICKI, JANET
|
LANKENAU INSTITUTE FOR MEDICAL RESEARCH
|
PA
|
$304,559
|
|
Orphan Drug
|
NINDS
|
5K08NS051349-03
|
|
Myoregenerative Potential of ABCB5+ Progenitors
|
FRANK, NATASHA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$133,920
|
|
Orphan Drug
|
NCI
|
5R01CA107268-05
|
|
Pharmacology of Targeted Therapy to Brain Tumors
|
SZOKA, FRANCIS
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$364,513
|
|
Orphan Drug
|
NINDS
|
5R01NS052325-03
|
|
Trophic Factor Signaling and Motor Neuron Death
|
KALB, ROBERT
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
PA
|
$287,877
|
|
Orphan Drug
|
NCI
|
5R01CA102774-05
|
|
A Mouse Model for Human Gastrointestinal Stromal Tumor
|
BESMER, PETER
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$354,934
|
|
Orphan Drug
|
NCI
|
2R01CA092104-05A2
|
|
Biologic Therapy for B-cell non-Hodgkin's Lymphoma
|
ANSELL, STEPHEN
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$258,741
|
|
Orphan Drug
|
NIAID
|
1R01AI071223-01A2
|
|
Experimental Molecular Vaccines for Schistosomiasis
|
SIDDIQUI, AFZAL
|
TEXAS TECH UNIVERSITY HEALTH SCIS CENTER
|
TX
|
$327,484
|
|
Orphan Drug
|
NCI
|
5R01CA102121-06
|
|
Role of Uridine Phosphorylase in Cancer Treatment
|
PIZZORNO, GIUSEPPE
|
NEVADA CANCER INSTITUTE
|
NV
|
$307,117
|
|
Orphan Drug
|
NIAID
|
5R44AI058362-04
|
|
BWA Host-Pathogen Innate Immune S/W Analysis Tools
|
DRAKE, KENNETH
|
SERALOGIX
|
TX
|
$515,225
|
|
Orphan Drug
|
NHLBI
|
5K24HL004212-09
|
|
Novel therapies in idiopathic pulmonary fibrosis
|
MARTINEZ, FERNANDO
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$84,906
|
|
Orphan Drug
|
NCI
|
5R01CA121131-03
|
|
PACAP Modulation of Shh Signaling in Medulloblastoma
|
LIAU, LINDA
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$266,286
|
|
Orphan Drug
|
NCI
|
5R01CA109474-03
|
|
Doxorubicin-Immunoconjugate Therapy of Non-Hodgkin's Lymphoma
|
STEIN, RHONA
|
CTR FOR MOLECULAR MEDICINE/IMMUNOLOGY
|
NJ
|
$255,220
|
|
Orphan Drug
|
NIAID
|
1R01AI073342-01A1
|
|
Molecular Detection of Blood Stream Infections in Women with Gynecologic Cancer
|
JORDAN, JEANNE
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$289,940
|
|
Orphan Drug
|
NCI
|
5R01CA114467-03
|
|
Prostaglandin Synthesis, Genetics and Colorectal Cancer
|
ULRICH, CORNELIA
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$555,937
|
|
Orphan Drug
|
NHLBI
|
1R01HL088151-01A1
|
|
NFATc3 in chronic hypoxic pulmonary hypertension
|
GONZALEZ BOSC, LAURA
|
UNIVERSITY OF NEW MEXICO
|
NM
|
$375,000
|
|
Orphan Drug
|
NCI
|
1R01CA125166-01A1
|
|
Transcriptional Repression of Sodium-Iodide Symporter in Thyroid Carcinoma
|
AIN, KENNETH
|
UNIVERSITY OF KENTUCKY
|
KY
|
$126,000
|
|
Orphan Drug
|
NHLBI
|
1R15HL091503-01
|
|
Lung Fibrosis in an Hermansky-Pudlak Syndrome Mouse Model
|
LYERLA, TIM
|
CLARK UNIVERSITY (WORCESTER, MA)
|
MA
|
$223,500
|
|
Orphan Drug
|
NHLBI
|
1R01HL085133-01A2
|
|
Novel Peptide for Dynamic Regulation of Lung Endothelium NOS/cGMP Functions
|
PATEL, JAWAHARLAL
|
UNIVERSITY OF FLORIDA
|
FL
|
$315,000
|
|
Orphan Drug
|
NCI
|
5R01CA118319-03
|
|
The Role of CBFb-MYH11 in Acute Myeloid Leukemia
|
MULLOY, JAMES
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
OH
|
$371,211
|
|
Orphan Drug
|
NCI
|
5R01CA120528-03
|
|
Validation of Prognostic and Diagnostic molecular tests in Mesothelioma
|
BUENO, RAPHAEL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$301,617
|
|
Orphan Drug
|
NCI
|
5R01CA067819-12
|
|
Clinical Trials of Flavopiridol with Chemotherapy
|
SCHWARTZ, GARY
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$679,347
|
|
Orphan Drug
|
NINDS
|
5K01NS055072-02
|
|
Identification of Novel Drugs against Huntington's Disease and Cerebral Ischemia
|
WANG, XIN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$177,012
|
|
Orphan Drug
|
NCI
|
5R01CA098372-05
|
|
GRPR Signaling in SCCHN: Integration with EGFR
|
GRANDIS, JENNIFER
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$230,921
|
|
Orphan Drug
|
NINDS
|
5R01NS051723-03
|
|
Time-lines of neural degeneration in ALS-PDC mouse model
|
SHAW, CHRISTOPHER
|
UNIVERSITY OF BRITISH COLUMBIA
|
CANADA
|
$262,170
|
|
Orphan Drug
|
NIDDK
|
5R01DK064969-05
|
|
CYTOCHROME P-450 AND GLOMERULAR PROTEIN PERMEABILITY
|
MCCARTHY, ELLEN
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
KS
|
$300,509
|
|
Orphan Drug
|
NCI
|
2R01CA103986-04A1
|
|
Vasculogenesis in Ewing's Sarcoma: Implications for Therapy
|
KLEINERMAN, EUGENIE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$254,023
|
|
Orphan Drug
|
NCI
|
5R01CA102575-04
|
|
Mechanism of gallbladder tumorigenesis in BK5.erbB2 mice
|
KIGUCHI, KAORU
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$224,720
|
|
Orphan Drug
|
NCI
|
5R01CA098550-05
|
|
Transcriptional Regulation of Myeloma Cell Growth
|
WICKREMA, AMITTHA
|
UNIVERSITY OF CHICAGO
|
IL
|
$224,093
|
|
Orphan Drug
|
NCI
|
5R01CA119066-03
|
|
Genetic Modifiers of the Anti-apoptotic Functions of Bcl-2
|
LOOK, A
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$303,525
|
|
Orphan Drug
|
NIAID
|
5R01AI060729-03
|
|
Stage-specific Signaling in Peripheral B Cell Selection
|
KHAN, WASIF
|
VANDERBILT UNIVERSITY
|
TN
|
$365,542
|
|
Orphan Drug
|
NINDS
|
5K08NS047983-05
|
|
Zebrafish Peripheral Sympathetic Nervous System Development and Neuroblastoma
|
GEORGE, RANI
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$132,422
|
|
Orphan Drug
|
NIAID
|
5R01AI048793-08
|
|
Immunogenetic Mechanisms of Vaccine Response
|
POLAND, GREGORY
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$539,350
|
|
Orphan Drug
|
NIDDK
|
1R01DK078075-01A1
|
|
Mechanisms of regulation of LRH-1, Nanog and SF-1 by DAX-1
|
FLETTERICK, ROBERT
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$371,548
|
|
Orphan Drug
|
NCI
|
1R01CA123451-01A2
|
|
Tryptophan Metabolism in Human Brain Tumors
|
JUHASZ, CSABA
|
WAYNE STATE UNIVERSITY
|
MI
|
$313,772
|
|
Orphan Drug
|
NCI
|
1R01CA124540-01A1
|
|
Multiple Roles of the API2 Moiety in API2-MALT1-Mediated Lymphomagenesis
|
MCALLISTER-LUCAS, LINDA
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$319,230
|
|
Orphan Drug
|
NCI
|
5R21CA116641-03
|
|
DUAL-AGENT NANOPARTICLES TO OVERCOME DRUG RESISTANCE
|
PANYAM, JAYANTH
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$149,500
|
|
Orphan Drug
|
NIDCR
|
5R01DE015945-05
|
|
P63 mediators as therapeutic targets in HNSCC
|
ELLISEN, LEIF
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$369,240
|
|
Orphan Drug
|
NHLBI
|
2R01HL068212-05A2
|
|
Protein Tyrosine Phosphatase and Hematopoietic Cell Regulation
|
QU, CHENG-KUI
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$386,250
|
|
Orphan Drug
|
NIGMS
|
2R01GM066492-06A1
|
|
Chemical Genetic and Biochemical Studies of Mitotic Proteolysis
|
KING, RANDALL
|
HARVARD UNIVERSITY (MEDICAL SCHOOL)
|
MA
|
$363,350
|
|
Orphan Drug
|
NCI
|
1R01CA123014-01A2
|
|
Genomic instability causes imatinib resistance in CML
|
SKORSKI, TOMASZ
|
TEMPLE UNIVERSITY
|
PA
|
$297,995
|
|
Orphan Drug
|
NHLBI
|
2R01HL066310-09
|
|
HIF- 2ALPHA, Hypoxic Gene Regulation, and Angiogenesis
|
SIMON, M
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$386,852
|
|
Orphan Drug
|
NCI
|
5R01CA041986-21
|
|
The Antitumor Antibiotics CC-1065 and the Duocarmycins
|
BOGER, DALE
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$408,808
|
|
Orphan Drug
|
NIAID
|
1R01AI065667-01A2
|
|
Non-replicative Vaccine for Human Brucellosis
|
VEMULAPALLI, RAMESH
|
PURDUE UNIVERSITY WEST LAFAYETTE
|
IN
|
$301,551
|
|
Orphan Drug
|
NIBIB
|
2R01EB001033-08A2
|
|
Acoustically Activated Micellar Drug Delivery
|
RAPOPORT, NATALYA
|
UNIVERSITY OF UTAH
|
UT
|
$338,251
|
|
Orphan Drug
|
NIGMS
|
1R01GM069754-01A3
|
|
Enzymology of Dimethylargininase
|
FAST, WALTER
|
UNIVERSITY OF TEXAS AUSTIN
|
TX
|
$252,360
|
|
Orphan Drug
|
NIA
|
2R01AG019259-06A2
|
|
Cardiac Amyloidosis in Aging African American
|
BUXBAUM, JOEL
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$466,883
|
|
Orphan Drug
|
NIAID
|
5R01AI065784-04
|
|
Arthropod vector-based vaccines for leishmaniasis
|
TITUS, RICHARD
|
COLORADO STATE UNIVERSITY-FORT COLLINS
|
CO
|
$429,970
|
|
Orphan Drug
|
NIGMS
|
5R37GM052382-12
|
|
Structure and Mechanism of Protein Prenyltransferases
|
BEESE, LORENA
|
DUKE UNIVERSITY
|
NC
|
$322,297
|
|
Orphan Drug
|
NCI
|
2R01CA090668-06A1
|
|
FLT3 Tyrosine Kinase Inhibitors as Therapy for Leukemia
|
SMALL, DONALD
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$293,612
|
|
Orphan Drug
|
NIAID
|
1R01AI070955-01A2
|
|
Identification of vaccine antigens based on expression in blood
|
BEERNINK, PETER
|
CHILDREN'S HOSPITAL & RES CTR AT OAKLAND
|
CA
|
$400,000
|
|
Orphan Drug
|
NCI
|
2R01CA056876-15A1
|
|
Hoxa9, Meis1, and Pbx in Self-renewal and Leukemogenesis
|
KAMPS, MARK
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$378,793
|
|
Orphan Drug
|
NINDS
|
1R21NS058369-01A1
|
|
A Zebrafish Model of Multiple System Atrophy
|
BURTON, EDWARD
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$162,422
|
|
Orphan Drug
|
NCI
|
1R01CA126939-01A1
|
|
The Epidemiology of Molecular Alterations in Mesothelioma
|
KELSEY, KARL
|
BROWN UNIVERSITY
|
RI
|
$496,312
|
|
Orphan Drug
|
NINDS
|
5R01NS055158-03
|
|
Small Molecular Therapeutics for Friedreich's Ataxia
|
GOTTESFELD, JOEL
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$414,010
|
|
Orphan Drug
|
NCI
|
1R01CA127239-01A1
|
|
pBACH1 binding site on BRCT(BRCA1): A novel approach to cancer therapeutics
|
NATARAJAN, AMARNATH
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
TX
|
$270,000
|
|
Orphan Drug
|
NCI
|
1R21CA132138-01A2
|
|
Evaluation of bioadhesive berry gels for oral cancer chemoprevention
|
MALLERY, SUSAN
|
OHIO STATE UNIVERSITY
|
OH
|
$218,025
|
|
Orphan Drug
|
NCI
|
5R13CA086959-09
|
|
The Annual Blood-Brain Barrier Consortium Meeting
|
NEUWELT, EDWARD
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$9,710
|
|
Orphan Drug
|
NIDCD
|
5R13CA086959-09
|
|
The Annual Blood-Brain Barrier Consortium Meeting
|
NEUWELT, EDWARD
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$4,855
|
|
Orphan Drug
|
NINDS
|
5R13CA086959-09
|
|
The Annual Blood-Brain Barrier Consortium Meeting
|
NEUWELT, EDWARD
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$10,000
|
|
Orphan Drug
|
NIGMS
|
5R01GM080742-02
|
|
Protein misfolding and aggregation
|
DOKHOLYAN, NIKOLAY
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$261,936
|
|
Orphan Drug
|
NCI
|
5R21CA121569-02
|
|
BLys inhibition using TACI-Fc in patients with B-bell non-Hodgkins' Lymphoma
|
ANSELL, STEPHEN
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$281,200
|
|
Orphan Drug
|
NCI
|
5R21CA125173-02
|
|
Novel Substrates of SCF Ubiquitin Ligases in Cell Cycle Control and Cancer
|
PAGANO, MICHELE
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$202,950
|
|
Orphan Drug
|
NCI
|
5R01CA109298-04
|
|
Ovarian Cancer: Mechanisms of Neuroendocrine Regulation
|
SOOD, ANIL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$271,595
|
|
Orphan Drug
|
NCI
|
5R21CA127822-02
|
|
Transcriptional control in the genesis of pancreatic intraepithelial neoplasia
|
AYER, DONALD
|
UNIVERSITY OF UTAH
|
UT
|
$179,400
|
|
Orphan Drug
|
NHLBI
|
2R37HL048129-14
|
|
Role and Regulation of Sodium, Potasium ATPase in Lung
|
SZNAJDER, JACOB
|
NORTHWESTERN UNIVERSITY
|
IL
|
$368,676
|
|
Orphan Drug
|
NINDS
|
5R01NS051756-03
|
|
Identification of Novel Drugs that Counter Huntington's Disease
|
FRIEDLANDER, ROBERT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$356,928
|
|
Orphan Drug
|
NHLBI
|
5R01HL066279-08
|
|
Differential GVHD induction by naive and memory T cells
|
SHLOMCHIK, MARK
|
YALE UNIVERSITY
|
CT
|
$396,896
|
|
Orphan Drug
|
NIDCR
|
5R01DE016586-04
|
|
Therapeutic Inhibition of Bcl-2 and Head & Neck Tumor Angiogenesis
|
NOR, JACQUES
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$336,787
|
|
Orphan Drug
|
NIDDK
|
2R01DK052334-11
|
|
Intestinal Growth Control
|
BEAUCHAMP, ROBERT
|
VANDERBILT UNIVERSITY
|
TN
|
$314,675
|
|
Orphan Drug
|
NINDS
|
5R37NS044687-26
|
|
Opening of the Blood Brain Barrier to Antitumor Agents
|
NEUWELT, EDWARD
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$617,969
|
|
Orphan Drug
|
NCI
|
5K99CA126980-02
|
|
Breast cancer stem cells and their cellular origin
|
LI, ZHE
|
CHILDREN'S HOSPITAL BOSTON
|
MA
|
$136,820
|
|
Orphan Drug
|
NIGMS
|
5F32GM078783-02
|
|
Catalytic, Asymmetric Aziridination using (Salen)metal Catalysts
|
WATSON, MARY
|
HARVARD UNIVERSITY
|
MA
|
$46,826
|
|
Orphan Drug
|
NIDCR
|
5R37DE013848-09
|
|
PS-341-induced Apoptosis in Squamous Cell Carcinoma
|
WANG, CUN-YU
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$318,577
|
|
Orphan Drug
|
NHLBI
|
1R01HL087948-01A1
|
|
A mouse model of myelodysplastic syndrome progression and leukemic stem cells
|
MA, YUPO
|
NEVADA CANCER INSTITUTE
|
NV
|
$450,000
|
|
Orphan Drug
|
NHLBI
|
1R01HL085769-01A2
|
|
Proteolysis of ultralarge von Willebrand factor and metabolic syndrome-diabetes
|
DONG, JING-FEI
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$382,018
|
|
Orphan Drug
|
NCI
|
2P50CA058207-14
|
9008
|
Biostatistics Core
|
MOORE, DAN
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$78,455
|
|
Orphan Drug
|
NIDDK
|
5R01DK047636-13
|
|
Hematopoietic specific Genes in Stem Cell Development
|
LIM, BING
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$334,101
|
|
Orphan Drug
|
NCI
|
2P01CA095616-06
|
0004
|
Identification and Characterization of Kinase Oncogenes in Glioblastoma
|
CHIN, LYNDA
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$217,878
|
|
Orphan Drug
|
NCI
|
1P01CA124570-01A1
|
0001
|
Genes In The Predisposition To Papillary Thyroid Carcinoma
|
DE LA CHAPELLE, ALBERT
|
OHIO STATE UNIVERSITY
|
OH
|
$330,439
|
|
Orphan Drug
|
NCI
|
1K08CA124479-01A1
|
|
Genome-wide promoter methylation profiling of glioma
|
LAI, ALBERT
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$136,500
|
|
Orphan Drug
|
NCI
|
2P50CA058183-14
|
0015
|
Treatment Resistance Pathways & Targeting Residula Cancers
|
CHANG, JENNY
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$155,217
|
|
Orphan Drug
|
NIDDK
|
1R01DK075635-01A2
|
|
Toll like receptor - Mediated pathways in liver injury
|
SZABO, GYONGYI
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
MA
|
$345,313
|
|
Orphan Drug
|
NCI
|
5R01CA120893-02
|
|
Dendritic Cell-Brain Tumor Stem Cell Fusion Vaccines
|
PLAUTZ, GREGORY
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
OH
|
$293,550
|
|
Orphan Drug
|
NCI
|
2R01CA103937-04
|
|
Molecular Diagnostics for Malignant Effusion
|
SHIH, IE-MING
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$338,148
|
|
Orphan Drug
|
NINDS
|
5R01NS056176-03
|
|
Attenuation of Axonal Damage and Neuronal Death in EAE
|
BANIK, NAREN
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
SC
|
$354,415
|
|
Orphan Drug
|
NHLBI
|
5R01HL081763-03
|
|
Epithelial Cell Cycle Regulation by Elastase
|
FISCHER, BERNARD
|
DUKE UNIVERSITY
|
NC
|
$227,214
|
|
Orphan Drug
|
NIAID
|
1R21AI073346-01A1
|
|
Novel Immunotherapy of African Trypanosomiasis
|
MANSFIELD, JOHN
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$220,500
|
|
Orphan Drug
|
NCI
|
1R21CA123313-01A2
|
|
Chemotherapy of Pancreatic Cancer: Induction of Apoptosis or Senescence
|
MODRAK, DAVID
|
CTR FOR MOLECULAR MEDICINE/IMMUNOLOGY
|
NJ
|
$249,885
|
|
Orphan Drug
|
NCI
|
1R21CA126055-01A1
|
|
Cetuximab for Treatment of High-risk Pre-malignant Upper Aerodigestive Lesions
|
CALIFANO, JOSEPH
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$369,000
|
|
Orphan Drug
|
NCI
|
1R21CA129590-01A1
|
|
Selenium as an adjuvant to imatinib therapy
|
DIAMOND, ALAN
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
IL
|
$176,625
|
|
Orphan Drug
|
NCI
|
5R21CA116826-02
|
|
Curcumin suppression of head and neck cancer
|
WANG, MARILENE
|
BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE
|
CA
|
$123,600
|
|
Orphan Drug
|
NIAID
|
5R01AI068109-02
|
|
Prophylactic Vaccines for Schistosomiasis
|
HARN, DONALD
|
HARVARD UNIVERSITY (SCH OF PUBLIC HLTH)
|
MA
|
$404,211
|
|
Orphan Drug
|
NIAID
|
5R01AI063360-03
|
|
Immune Response to Polyomavirus Infection
|
RANDHAWA, PARMJEET
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$385,400
|
|
Orphan Drug
|
NCI
|
1R43CA132207-01
|
|
Anti-cancer Drig Sensitizers
|
ROYER, ROBERT
|
QUATROS RESEARCH AND DEVELOPMENT, LLC
|
NM
|
$135,800
|
|
Orphan Drug
|
NCI
|
2R01CA101135-05A1
|
|
Molecular Characterization of Cell-Cell Interactions in Cancer Metastasis
|
KONSTANTOPOULOS, KONSTANTINOS
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$289,164
|
|
Orphan Drug
|
NCI
|
1R01CA129528-01A1
|
|
Converting an Oncogene to an Apoptotic Factor by Manipulating Signal Sequences
|
LIM, CAROL
|
UNIVERSITY OF UTAH
|
UT
|
$283,185
|
|
Orphan Drug
|
NIAID
|
1R21AI070787-01A2
|
|
RNA aptamers as novel antidotes against botulism
|
CAI, SHUOWEI
|
UNIVERSITY OF MASSACHUSETTS DARTMOUTH
|
MA
|
$204,386
|
|
Orphan Drug
|
NCI
|
1R01CA127927-01A1
|
|
Prediction of Neoadjuvant Chemo Pathological Response Using MRI Markers
|
SU, MIN-YING
|
UNIVERSITY OF CALIFORNIA IRVINE
|
CA
|
$488,611
|
|
Orphan Drug
|
NCRR
|
1S10RR024653-01
|
|
Circular Dichroism Spectrometer
|
ROUSSEAU, DENIS
|
YESHIVA UNIVERSITY
|
NY
|
$150,187
|
|
Orphan Drug
|
NCI
|
5R01CA109446-05
|
|
Recombinant Immunotherapy for Renal Cell Carcinoma
|
GRIFFITH, THOMAS
|
UNIVERSITY OF IOWA
|
IA
|
$258,035
|
|
Orphan Drug
|
NINDS
|
5K23NS055733-02
|
|
Cognition in Clinical Trials for Huntington's Disease
|
BEGLINGER, LEIGH
|
UNIVERSITY OF IOWA
|
IA
|
$155,145
|
|
Orphan Drug
|
NIDDK
|
5K01DK063992-05
|
|
Gene therapy for Cooley's anemia in a new mouse model
|
RIVELLA, STEFANO
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
NY
|
$129,133
|
|
Orphan Drug
|
NINDS
|
5R01NS051462-04
|
|
Increased persistent sodium current in SOD1 motoneurons
|
HECKMAN, CHARLES
|
NORTHWESTERN UNIVERSITY
|
IL
|
$314,445
|
|
Orphan Drug
|
NINDS
|
5K08NS055061-03
|
|
Macrophage and Microglial Activation in Glioma-Associated Inflammation
|
GUPTA, NALIN
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$161,406
|
|
